| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 11015126 | Chest | 2018 | 4 Pages |
Abstract
Idiopathic pulmonary fibrosis is the most common idiopathic interstitial pneumonia. Prognosis is poor with a median survival <3 years. Pirfenidone is one of two US Food and Drug Administration-approved medications that slow disease progression. We describe the development of lymphadenopathy or a sarcoid-like reaction following initiation of pirfenidone, a complication not previously reported.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Nicholas A. MD, Jasleen MD, Kirk D. MD, Steven R. MD, Lorriana E. MD,